F-box protein 6Genealiases: FBG2 · FBS2 · FBX6 · Fbx6b
Q-omics provides the consensus-scored FBXO6 profile across patient tissues and cancer cell-line models. FBXO6 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, FBXO6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FBXO6 protein abundance shows 24,980 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, KIRC, and PDAC as cancer lineages where FBXO6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO6 survival associations across molecular data types. FBXO6 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO6 RNA expression–survival associations across cancer types. High FBXO6 expression shows unfavorable associations in KICH, KIRC, LGG and LIHC, but favorable associations in BLCA and SKCM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for FBXO6 RNA expression.
This table summarizes FBXO6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO6 shows lower tumor expression in KICH and higher tumor expression in KIRC, BLCA, HNSC, THCA and STAD. The KIRC box plot shows higher FBXO6 RNA expression in tumor versus normal tissue (log2 FC = +1.416, t-test p < 0.001).
This table shows molecular features associated with FBXO6 in patient tissues and cancer cell lines. In patient samples, FBXO6 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
